Cargando…

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China

OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Han, Ying, Yang, Jianliang, Liu, Peng, He, Xiaohui, Zhang, Changgong, Zhou, Shengyu, Zhou, Liqiang, Qin, Yan, Song, Yongwen, Liu, Yueping, Wang, Shulian, Jin, Jing, Gui, Lin, Sun, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433587/
https://www.ncbi.nlm.nih.gov/pubmed/30996573
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10
_version_ 1783406302305714176
author Shi, Yuankai
Han, Ying
Yang, Jianliang
Liu, Peng
He, Xiaohui
Zhang, Changgong
Zhou, Shengyu
Zhou, Liqiang
Qin, Yan
Song, Yongwen
Liu, Yueping
Wang, Shulian
Jin, Jing
Gui, Lin
Sun, Yan
author_facet Shi, Yuankai
Han, Ying
Yang, Jianliang
Liu, Peng
He, Xiaohui
Zhang, Changgong
Zhou, Shengyu
Zhou, Liqiang
Qin, Yan
Song, Yongwen
Liu, Yueping
Wang, Shulian
Jin, Jing
Gui, Lin
Sun, Yan
author_sort Shi, Yuankai
collection PubMed
description OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site. RESULTS: In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer’s ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer’s ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%. CONCLUSIONS: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.
format Online
Article
Text
id pubmed-6433587
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-64335872019-04-17 Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China Shi, Yuankai Han, Ying Yang, Jianliang Liu, Peng He, Xiaohui Zhang, Changgong Zhou, Shengyu Zhou, Liqiang Qin, Yan Song, Yongwen Liu, Yueping Wang, Shulian Jin, Jing Gui, Lin Sun, Yan Chin J Cancer Res Original Article OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site. RESULTS: In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer’s ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer’s ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%. CONCLUSIONS: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis. AME Publishing Company 2019-02 /pmc/articles/PMC6433587/ /pubmed/30996573 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10 Text en Copyright © 2019 Chinese Journal of Cancer Research. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Original Article
Shi, Yuankai
Han, Ying
Yang, Jianliang
Liu, Peng
He, Xiaohui
Zhang, Changgong
Zhou, Shengyu
Zhou, Liqiang
Qin, Yan
Song, Yongwen
Liu, Yueping
Wang, Shulian
Jin, Jing
Gui, Lin
Sun, Yan
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
title Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
title_full Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
title_fullStr Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
title_full_unstemmed Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
title_short Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
title_sort clinical features and outcomes of diffuse large b-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 who classified cases in a single institution in china
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433587/
https://www.ncbi.nlm.nih.gov/pubmed/30996573
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10
work_keys_str_mv AT shiyuankai clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT hanying clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT yangjianliang clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT liupeng clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT hexiaohui clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT zhangchanggong clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT zhoushengyu clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT zhouliqiang clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT qinyan clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT songyongwen clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT liuyueping clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT wangshulian clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT jinjing clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT guilin clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina
AT sunyan clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina